<< Back to all news coverage

American College of Cardiology Education Always Learning (ACCEL): March 2018

Podcast: ACCEL Lite - ACCEL Interview From ACC.18

Dr. Jeffrey Olgin, co-principal investigator of the VEST Trial, discusses the VEST results with Dr. Noel Bairey Merz, director of the Women's Heart Center at the Cedars-Sinai Heart Institute, following a Late-Breaking Clinical Trial Session presentation at the American College of Cardiology’s 67th Annual Scientific Session in Orlando, Florida.

VEST is the first multi-center, randomized controlled trial of the wearable cardioverter defibrillator (WCD), studying 2,302 patients who had a recent MI and a low-EF.

The WCD is prescribed for patients at risk of SCD, including patients with a low EF who have recently suffered a heart attack or have a new diagnosis of heart failure. LifeVest gives physicians time to optimize medical therapy and assess a patient’s long-term risk for sudden cardiac death (SCD).

<< Back to all news coverage